echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > JCO: The effect of oral azacitidine on patients with low-risk myelodysplastic syndromes

    JCO: The effect of oral azacitidine on patients with low-risk myelodysplastic syndromes

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Journal of Clinical Oncology published a study online that showed that although CC-486 can increase the proportion of patients with LR-MDS that do not rely on red blood cell transfusion, it may increase the risk of early death.


    Screenshot of the cover of the paper

    Screenshot of the cover of the paper

    Myelodysplastic Syndrome (MDS) covers a group of blood system diseases characterized by myelodysplastic proliferation and peripheral blood cytopenia.


    The experiment recruited patients from 101 locations in 20 countries/regions from April 2013 to February 2018.


    Technical route

    Technical route




    CC-486 can reduce the blood transfusion burden of RBC and improve thrombocytopenia in LR-MDS patients with symptomatic diseases and refractory cytopenias, but the CC-486 group has a higher incidence of early death

     

    references:

    references:

    Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V , Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A.


    Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V , Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A.


    org/doi/10.
    1200/JCO.
    20.
    02619?url_ver=Z39.
    88-2003&rfr_id=ori:rid:crossref.
    org&rfr_dat=cr_pub%20%200pubmed">https://ascopubs.
    org/doi/10.
    1200/JCO.
    20.
    02619?url_ver=Z39.
    88-2003&rfr_id=ori:rid:crossref.
    org&rfr_dat=cr_pub%20%200pubmed
    org/doi/10.
    1200/JCO.
    20.
    02619?url_ver=Z39.
    88-2003&rfr_id=ori:rid:crossref.
    org&rfr_dat=cr_pub%20%200pubmed"> https://ascopubs.
    org/doi/10.
    1200/JCO .
    20.
    02619?url_ver=Z39.
    88-2003&rfr_id=ori:rid:crossref.
    org&rfr_dat=cr_pub%20%200pubmed
    https://ascopubs.
    org/doi/10.
    1200/JCO.
    20.
    02619?url_ver=Z39.
    88-2003&rfr_id=ori: rid:crossref.
    org&rfr_dat=cr_pub%20%200pubmed


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.